(NASDAQ: CTMX) Cytomx Therapeutics's forecast annual revenue growth rate of 46.69% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.94%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.33%.
Cytomx Therapeutics's revenue in 2026 is $14,027,000.On average, 9 Wall Street analysts forecast CTMX's revenue for 2026 to be $5,692,544,471, with the lowest CTMX revenue forecast at $3,204,672,324, and the highest CTMX revenue forecast at $12,292,207,414. On average, 9 Wall Street analysts forecast CTMX's revenue for 2027 to be $8,792,356,429, with the lowest CTMX revenue forecast at $3,204,672,324, and the highest CTMX revenue forecast at $19,388,267,560.
In 2028, CTMX is forecast to generate $9,148,140,458 in revenue, with the lowest revenue forecast at $1,281,868,930 and the highest revenue forecast at $19,388,267,560.